Firm in China Must Resolve All FDA Concerns to Resume Exporting API to U.S.
This article was originally published in The Gold Sheet
Executive Summary
Kunshan Chemical and Pharmaceutical Co. of Kunshan City, China, has corrected or begun to correct many of the deficiencies cited in a Sept. 6 warning letter from FDA. However, until it remedies all outstanding deficiencies, including problems with documentation of batch production records and method validation, lab equipment calibration and production equipment cleaning and maintenance, "any future shipments of APIs manufactured at the Kun Tai Road site (Old Site) will be denied entry into the United States," Richard Friedman, director of the Division of Manufacturing and Product Quality in CDER's Office of Compliance, said in the letter, which was based on an April 2007 inspection of that site and the new Provincial Highway site. Kunshan said it was not shipping API from the old site to the U.S., but FDA had information to the contrary
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.